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Abstract
Background: Human stem cells are viewed as a possible source of neurons for a cell-based
therapy of neurodegenerative disorders, such as Parkinson's disease. Several protocols that
generate different types of neurons from human stem cells (hSCs) have been developed.
Nevertheless, the cellular mechanisms that underlie the development of neurons in vitro as they are
subjected to the specific differentiation protocols are often poorly understood.
Results: We have designed a focused DNA (oligonucleotide-based) large-scale microarray
platform (named "NeuroStem Chip") and used it to study gene expression patterns in hSCs as they
differentiate into neurons. We have selected genes that are relevant to cells (i) being stem cells, (ii)
becoming neurons, and (iii) being neurons. The NeuroStem Chip has over 1,300 pre-selected gene
targets and multiple controls spotted in quadruplicates (~46,000 spots total). In this study, we
present the NeuroStem Chip in detail and describe the special advantages it offers to the fields of
experimental neurology and stem cell biology. To illustrate the utility of NeuroStem Chip platform,
we have characterized an undifferentiated population of pluripotent human embryonic stem cells
(hESCs, cell line SA02). In addition, we have performed a comparative gene expression analysis of
those cells versus a heterogeneous population of hESC-derived cells committed towards neuronal/
dopaminergic differentiation pathway by co-culturing with PA6 stromal cells for 16 days and
containing a few tyrosine hydroxylase-positive dopaminergic neurons.
Conclusion: We characterized the gene expression profiles of undifferentiated and dopaminergic
lineage-committed hESC-derived cells using a highly focused custom microarray platform
(NeuroStem Chip) that can become an important research tool in human stem cell biology. We
propose that the areas of application for NeuroStem microarray platform could be the following:
(i) characterization of the expression of established, pre-selected gene targets in hSC lines,
including newly derived ones, (ii) longitudinal quality control for maintained hSC populations, (iii)
following gene expression changes during differentiation under defined cell culture conditions, and
(iv) confirming the success of differentiation into specific neuronal subtypes.
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Modern DNA microarrays permit a comprehensive analy-
sis of quantitative and qualitative changes in RNA tran-
script abundance, outlining the cross-sections of gene
expression and alterations of these in response to genetic
or environmental stimuli. Genome-scale microarrays
(cDNA- or oligonucleotide-based) are most valuable
when screening populations of cells for the novel genes
reflecting potential diagnostic and prognostic markers or
for an identification of novel therapeutic targets. On the
other hand, custom microarray platforms that focus on
specific pre-selected subset of genes relevant to a particu-
lar field of investigation can be less costly and more suita-
ble for detection of smaller gene expression changes.
Microarray technology has added important information
on both normal development and pathological changes
in neurons. This is well illustrated by multiple studies on
substantia nigra dopaminergic neurons, which degenerate
in Parkinson's disease (PD) [1-5]. The shortcomings of
pharmacological therapies in PD have stimulated a search
for alternative treatment strategies. In successful cases,
transplants of human embryonic mesencephalic
dopaminergic neurons can both restore dopaminergic
neurotransmission and provide some symptomatic relief
[6-8]. A wider application of neural transplantation in PD
is, however, currently not feasible due to the unpredicta-
ble and variable outcome, the risks of unwanted side-
effects (dyskinesias) [9,10] and ethical and practical prob-
lems associated with using donor cells obtained from
aborted embryos and fetuses [11,12]. Human embryonic
stem cells (hESCs) are considered a promising future
source of cells for cell replacement therapy in PD and
other neurological conditions [13]. They could constitute
a virtually infinite source of self-renewing cells that can be
persuaded to differentiate into specific types of neural
cells, including dopaminergic neurons [14-16]. The
molecular mechanisms that govern development of cul-
tured hESCs into specific types of neural cells are not fully
understood. To promote our understanding of such
mechanisms, it would be valuable to have tools that read-
ily and reproducibly can help to characterize the cells as
they differentiate from pluripotent stem cells into post-
mitotic neurons. This important issue was addressed in
earlier studies by Luo et al. and Yang et al., who designed
small-to-moderate scale custom microarray platforms
(281 and 755 gene targets, respectively) [17,18]. In addi-
tion SuperArray Bioscience Corporation (Frederick, MD,
USA) have manufactured a range of small-scale arrays
(263 gene targets for human array; [19]). We sought to
create an improved and updated microarray platform for
hESC/neuronal differentiation-oriented gene expression
studies. Therefore, we generated a specialized large-scale
DNA microarray platform (the "NeuroStem Chip") that
has over 1,300 pre-selected gene targets and multiple con-
trols spotted in quadruplicates (~46,000 spots total). Here
we introduce the platform and the advantages it can offers
to neuroscientists and stem cell biologists: particularly, in
the niche of gene expression-oriented characterization of
the samples using an assay of pre-selected, already estab-
lished gene targets. In the current study, we use the Neu-
roStem Chip to characterize an undifferentiated
population of pluripotent hESCs (cell line SA02, Cellartis
AB, Göteborg, Sweden) and compare the gene expression
in those cells with that of a hESC-derived cell population
rich in neurons, including tyrosine hydroxylase-positive
dopaminergic neurons.
Results and Discussion
Stem cells have unique biological characteristics, but only
a limited number of genes are currently recognized as
established stem cell markers. Examples include POU
domain, class 5, transcription factor 1 (Oct3/4), signal
transducer and activator of transcription 3 (Stat3), terato-
carcinoma-derived growth factor (Tdgf1), Enk-pending
(Nanog), undifferentiated embryonic cell transcription
factor 1 (Utf1) and DNA methyltransferase 3B (Dnmt3b)
[20]. At the same time, hundreds of genes are suggested as
candidate markers for "stemness", but their coupling to
the undifferentiated stem cell state is not yet fully verified
[21]. The concept of "stemness" (term introduced in 1986
by Grossman & Levine) is defined as "core stem cell proper-
ties that underlie self-renewal and the ability to generate differ-
entiated progeny" [22]. Considering the complexity of the
processes involved, stemness can hardly be ensured by co-
operation of just a few genes. Nevertheless, three stemness
genes (namely, Oct3/4, Stat3 and Nanog) are considered
"master"-genes that control the self-renewing process
[23,24]. Various types of stem cells, such as hematopoi-
etic, mesenchymal and neural (HSCs, MSCs and NSCs,
respectively), embryonic germ and embryonic carcinoma
cells (EGCs and ECCs, respectively) are all characterized
by variations in gene expression profiles, and only a few
gene markers are associated with all these cell types
[25,26]. We have aimed to embrace the most comprehen-
sive set of those genes into a solitary array, the NeuroStem
Chip. Thereby, it is possible to employ it to monitor the
relative expression levels of numerous known and candi-
date stemness genes in a single experiment.
Similar to the genetic bases underlying stemness, cell dif-
ferentiation is associated with altered expression levels of
certain recognized or candidate genes [25]. We therefore
incorporated gene markers of development and differen-
tiation in general, and that of neuronal and dopaminergic
differentiation in particular, into the NeuroStem Chip.
Examples include markers for the processes of neuronal
maturation, axonal branching, neural/neuronal survival,
etc. Finally, we ensured that known markers for specific
types of neurons, allowing identification of individual cellPage 2 of 15
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to genes associated with the differentiation and matura-
tion of dopaminergic neurons. In many published stud-
ies, the expression of only a single (tyrosine hydroxylase,
TH) or 2–3 markers for dopaminergic neurons (e.g.
amino acid decarboxylase (AADC), dopamine transporter
(DAT), vesicular monoamine transporter 2 (VMAT2))
have been used to indicate dopaminergic identity of neu-
rons. In contrast, the NeuroStem Chip includes oligonu-
cleotide probes for 88 genes related to dopaminergic
neurons, thus being more comprehensive in this sense,
compared to other existing microarray platforms, includ-
ing focused ones [17,18]. Those entries encompass recog-
nized and candidate markers for dopaminergic neurons
(mature and early) and progenitors, as well as markers for
the maturation and differentiation of the latter (Table 1).
Table 2 represents conditional functional breakdown of
genes targeted by the NeuroStem microarray platform. A
number of important gene groups that are included in the
chip are not mentioned in Table 2. Among these, entries
related to Dickkopf gene family, galanin-, melatonin-,
vasoactive intestinal peptide (VIP)-, cAMP response ele-
ment-binding protein (CREB)- and B cell leukemia 2
(Bcl2) oncogene-related are present. Many of them play
potentially important, yet undefined, roles in the biology
of stem cells. Additionally, we included some genes impli-
cated in disease mechanisms of neurodegenerative disor-
ders (most importantly, Parkinson's disease and
Alzheimer's disease) in the chip. Furthermore, we incor-
porated a number of markers for distinct differentiation
pathways (e.g. hematopoietic and pancreatic) and cell
types (e.g. cancer subtypes and a range of normal cell
types) to serve as essential controls. Taken together, we
believe that in its present form NeuroStem Chip repre-
sents currently most comprehensive gene expression plat-
form for studies on stem cells, neural/neuronal
differentiation, human neurodegeneration and neuronal
survival, both in vivo and in vitro. The complete layout of
NeuroStem Chip will be disclosed to the academic com-
munity, upon request.
The microarray format we selected relies on long oligonu-
cleotide molecules (69–71 nucleotides) printed over a
solid surface. We spotted the synthesized oligonucleotides
(Operon Biotechnologies) with a constant concentration
across the slides, and evaluated the quality and consist-
ency of spotting in a series of control experiments. We
then illustrated the utility and technical reliability of the
NeuroStem Chip by characterizing the gene expression
profile of commonly utilized hESC line SA02 (Sahlgren-
ska 2; [27]), including (i) undifferentiated cells and (ii)
cells committed towards neuronal/dopaminergic differ-
entiation pathway. For the first of these, we used total
RNA sample purified from hESC colonies that exhibited
morphology consistent with cell proliferation and the
absence of spontaneous differentiation (Figure 1A). We
also evaluated the expression of the cell cycle marker Ki67
and the pluripotency marker OCT3/4 in the sample by
immunocytochemistry (Figure 1B–E). Co-culturing of
ESCs with murine stromal cells (including PA6 cell line)
rapidly generates dopaminergic neurons from ESCs by an
unexplained mechanism termed stromal cell-derived
inducing activity (SDIA; [28,29]). We therefore commit-
ted hESCs toward the neuronal/dopaminergic differentia-
tion pathway by co-culturing with PA6 cells for 16 days,
resulting in appearance of cells positive for early and late
neuronal markers, including nestin, β-III-tubulin, and TH,
Table 1: NeuroStem chip entries related to dopaminergic system.
Genesa Function
Aadc, Ant2 (Slc25a5), Calb1, Dat (Slc6a3), Girk2 (Kcnj6), Igf1, Ptx3, Th Markers of dopaminergic neurons
En1, En2, Lmx1bb, Pax5, Shh, Wnt1 Markers of dopaminergic progenitors
Adh2, Lhx1 (Lim1), Lhx5 (Lim2) Markers of dopaminergic progenitors maturation
Drd2b, Vmat2 Markers of mature dopaminergic neurons
Gfra1, Gfra2, Gfra3, Gfra4, Otx2 Markers of early dopaminergic neurons
Dlx1, Dlx2, Flj38973, Lmx1a Related to differentiation of dopaminergic neurons
Adcy7, Alcam, Art (Artn), Bcl11a, Calca, Cart, Cbln1, Cdh2, Col11a1, Cx43, D1lip (Drd1ip), 
Darpp32 (Ppp1r1b), Dbh, Doc2a, Drd1, Drd3, Drd4, Drd5, Drip78 (Dnajc14), Egln3 (Phd3), 
Egr1, Fos, Fxyd6, Galm, Ghr, Grin2c, Grp, Gsbs (C7orf16), Hs6st2, Igfbp4, Kcna5, Kcnab1, 
Math2, Mlp (Marcksl1), Moxd1, Mpp3, Nrip3, Nrp2, Nt (Nts), Ntn (Nrtn), Nurr1 (Nr4a2), Pac1 
(Adcyap1r1), Pacap, Plagl1 (Zac), Pvrl3 (Nectin 3), Rab3c, Rcn1, Slc17a6 (Vglut2), Slc6a1, Sox6, 
Spp1, Tacr3, Trhr, Zfp161, Vav3, Zdhhc2
Related to dopaminergic system
The majority of genes listed may also possess other functions, not related to dopaminergic system. Four entries were omitted from the table, 
representing candidate markers of dopaminergic system now undergoing characterization (unpublished data).
a Italics indicates genes up-regulated (Log2 ratio >1.0) in dopaminergic differentiation experiment. Rcn1, Log2 ratio >0.97; Fxyd6 and Zfp161, Log2 
ratio >0.7).
b May also possess other functions related to dopaminergic system.Page 3 of 15
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Table 2: Selected categories of NeuroStem chip entries.
Category Functional role Examples
I. Stemness Recognized markers of stemness Oct3/4, Nanog, Tdgf1
Candidate markers of stemness Cpxm1, Hook1, Ddx21
Germ cell markers Rif1, Bnc1, Bnc2
Hematopoietic stem cell markers Hoxb4, Cdcp1, C1qr1
Mesenchymal stem cell marker Bmpr1a, Bmpr2, Cd49a
II. Proliferation Proliferation markers Ki67, Pcna, Myc
Neural proliferation markers Emx1, Gbx2
III. Development Differentiation Lifr, Ebaf, Lyar
Neuronal differentiation Ren, Rai1, Neurod2
Dopaminergic differentiation Dlx1, Dlx2, Lmx1a
Neuronal maturation Mecp2, Ebf3, Sox4
Neuronal process formation Hmgb1, Rage
Axonal elongation and branching Pi3, Map1b, Slit1
IV. Neural markers Pan-neural markers Gap43, Nfh, Eno2
Markers of dopaminergic neurons Th, Aadc, Dat
Markers of cholinergic neurons Ngf
Markers of spinal neurons Hoxc6
Glial markers S100β, Cd68
Astrocyte markers Gfap, Tapa1
Oligodendrocyte markers Mag, Mobp, Omg
V. Distinct markers Normal tissues
Liver Gata6, G6pd, Fabp1
Pancreas Tff3, Sst, Pax4
Skeletal muscle Itga7, Dmd, Tnnt3
Cardiac muscle Nkx2.5, Anf, Myhca
Smooth muscle Actg2, Cnn1, Sm22α
Endothelial cells Flt1, Vwf, Pecam1





Prostatic cancer Hpn, Mat8
Lung cancer Rab5a, Tp63
Ovarian cancer Mgb2
Hodgkin's lymphoma Ptp4a, Atf5, p21snft
VI. Relevant groups Apoptosis-related p53, Psip1, Birc2
Telomere-related Tert, Terf2, Rap1
Antioxidants Sod1, Sod2, Gpx1
Imprinted genes Tseb3, Gnas1, Grb10
FZD group Fzd1, Fzd3, Sfrp1
WNT group Wnt1, Wnt7a, Wisp1
BMP group Bmp1, Bmp2, Bambi
STAT group Stat1, Stat3, Pias1
FGF group Fgf1, Fgf2, Fgfr4
GDF group Gdf2, Gdf3, Gdf9
Caspases group Casp1, Casp2, Hsp70
Cyclins group Ccna1, Ccnc, Cdk1
Kruppel-like group Klf2, Klf9, Znf184
Due to functional redundancy, individual genes may fit into more than one category.
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2). To verify the expression of some key stem cell- and
neural phenotype-associated genes we performed RT-PCR
comparing RNA samples from the undifferentiated hESCs
with hESCs of the same line differentiated toward neuro-
nal/dopaminergic pathway, as described above. The
expression profile outlined by RT-PCR confirmed the
identity of the sample used (Figure 3). After performing
RNA integrity tests, we incorporated fluorescent labels to
the amplified RNA samples from hESCs (Cyanine 3-CTP
(Cy3) and Cyanine 5-CTP (Cy5)), hESC-derived cells con-
taining TH-positive neurons (Cy3 and Cy5) and human
universal reference RNA (Cy5), and hybridized aliquots
with NeuroStem microarray slides using the following
conditions: hESC vs. reference, Cy3 : Cy5 = (i) 20:10
pmol, and (ii) 10:5 pmol; and hESC vs. hESC-derived
cells, Cy3 : Cy5 = (iii) 30:20 pmol, respectively. Universal
reference RNA has been previously established as a stand-
ard reference material for microarray experiments, prov-
ing an ability to effectively hybridize to a large fraction of
microarray spots [30].
We performed two-color hybridizations (e.g. for the
experiment vs. reference) following an established proto-
col [31], and included dye-flip technical replicates in the
analysis (Figure 4). Using the online software program
BASE [32] we sequentially filtered the data by background
subtraction, negative flagging, negative intensities and for
inconsistent data amongst replicates [33]. Figure 5A
shows a comparison of the spot intensities prior to nor-
malization (M versus A plot), with the Log2 of the expres-
sion ratio between Cy3/Cy5 being plotted as a function of
the log10 of the mean of the total expression intensities
for Cy3 and Cy5 channels. The deviation of the line from
zero revealed a need for normalization, so prior to data
analyses we normalized signals using a locally weighted
scatterplot-smoothing regression (LOWESS) algorithm
(Figure 5A–B; fitted line) implemented in BASE. Since the
reproducibility of two-color microarray gene expression
data is critically important, we calculated Pearson correla-
tion coefficients of the reporters present in the filtered
database comparing the average expression ratios (7005
for hESCs vs. universal reference; 6947 for undifferenti-
ated vs. neuronal/dopaminergic lineage-committed
hESCs). Results obtained revealed that data were consist-
ent across technical replicates (dye-swap and amount of
loaded material), showing general high reproducibility:
e.g., correlation coefficients were greater than 0.96 for
technical replicates and 0.78 for dye-swapping samples in
hESCs vs. universal reference hybridizations (Table 3). To
detect genes with high expression levels in hESC samples,
we filtered data for intensity values >100 in the hESC sam-
ple and performed clustering analysis using the TIGR Mul-
tiExperiment Viewer (MEV; [34]). To visualize variations
of spot/reporter per technical replicate, hierarchical clus-
tering was performed by K-means classifier based on the
linear-correlation-based distance (Pearson, centred)
method. The optimal number of clusters was determined
empirically to produce the most balanced ratio of entries
to cluster of highly expressed genes. A cluster of 101 genes
up-regulated in the hESC sample [see Additional file 1],
was plotted in a centroid graph (Figure 5C); the variation
across technical replicates was low. We merged technical
replicates to generate a list of the most up-regulated genes
expressed in the hESC sample compared to the universal
reference RNA (Table 4). Standard error of the mean
expressed as percentage was calculated for the 4 technical
replicates, and was 6.7% for the top 25 genes up-regulated
in hESC samples, compared to universal reference RNA.
We performed the analysis of microarray data, as
described in the Methods, and spot error values were gen-
erally in the lower range, indicating high stringency of the
signals and low variance.
As seen in Table 4 and Table 5, the NeuroStem Chip iden-
tified numerous genes associated with stem cells. In par-
ticular, homeo box expressed in ES cells 1 (Hesx1) gene
was identified as the most up-regulated in the ES cell prep-
aration, compared to universal reference RNA. Highly
expressed in pluripotent ESCs, Hesx1 expression is down-
regulated upon embryonic stem cell differentiation
[35,36], as also clearly seen in differentiation experiment
of our own (Table 4). Similarly, Gremlin 1 homolog,
cysteine knot superfamily gene (Grem1, also known as
Cktsf1b1 and Dand2) is a recognized factor of cell-fate
determination of ESCs [37]. Many more genes highly up-
regulated in the hESC sample in comparison with univer-
sal reference RNA are associated with stem cells: further
examples include Gap junction protein α1 (Gja1) and Zic
family member 3 heterotaxy 1 (Zic3) (Table 4) [20]. The
expression of fibroblast growth factor receptor 2 (Fgfr2) is
of particular interest. Basic fibroblast growth factor (FGF2,
bFGF) supports hESC proliferation and their ability to
maintain undifferentiated phenotype when cultured in
vitro [38,39]. Moreover, in some hESC lines a very high
concentration of FGF2 could substitute for the need of
feeder cells [40]. At the same time, genes listed in Table 4
represent the most highly up-regulated entries in a rela-
tively limited group of genes (Figure 5C). Many other
genes involved in maintenance of ESC phenotype (i.e.
established or candidate markers of stem cells) have lower
levels of expression (Table 5). Examples include undiffer-
entiated embryonic cell transcription factor 1 (Utf1),
DNA methyltransferase 3B (Dnmt3b), developmental
pluripotency associated 4 (Dppa4, a newly established
pluripotency marker [41]) and numerous candidate
markers of "stemness": e.g. genes for KIAA1573 protein,
forkhead box O1A (Foxo1a), high-mobility group box 1
(Hmgb1), C-terminal binding protein 2 (Ctbp2) and left-
right determination factor 1 (Lefty1), as well as others. ForPage 5 of 15
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Human Embryonic Stem Cells (hESCs) used in a studyFigure 1
Human Embryonic Stem Cells (hESCs) used in a study. (A) Phase contrast image of unaltered hESC colony. Immunocytochem-
ical analysis of (B) Ki67, (C) OCT3/4, (D)DAPI, (E) Merge. Scale bars = 100 µm.
Human Embryonic Stem Cell (hESCs)-derived cells committed toward neuronal/dopaminergic differentiation pathway by co-culturing with PA6 s romal cells for 16 daysFig e 2
Human Embryonic Stem Cell (hESCs)-derived cells committed toward neuronal/dopaminergic differentiation pathway by co-
culturing with PA6 stromal cells for 16 days. (A, B) Phase contrast images of structures formed in hESC colonies. (C) Immuno-
cytochemical analysis of cell composition: tyrosine hydroxylase (TH), green; human nuclei marker, red. Scale bars = 100 µm.
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Table 3: Pearson correlation coefficients of assay comparisons.
hES (Cy3) : Ref (Cy5), 10:5 pmol hES (Cy5) : Ref (Cy3), 10:5 pmol hES (Cy3) : Ref (Cy5), 20:10 pmol
hES (Cy3) : Ref (Cy5), 10:5 pmol X X X
hES (Cy5) : Ref (Cy3), 10:5 pmol 0.787 X X
hES (Cy3) : Ref (Cy5), 20:10 pmol 0.966 0.821 X
hES (Cy5) : Ref (Cy3), 20:10 pmol 0.816 0.961 0.846
Ref, Human Universal Reference RNA (Stratagene, USA).
RT-PCR analysis of RNA samples used and validation of microarray resultsFigure 3
RT-PCR analysis of RNA samples used and validation of microarray results. Ratio, ratio of differentiated (Day 16)/undifferenti-
ated (Day 0) hESC sample normalized spot intensity as detected by microarray analysis (average value from all spots). M, 100 
bp DNA ladder; Day 0, undifferentiated hESCs; Day 16, hESCs committed to neuronal/dopaminergic differentiation pathway by 
co-culturing with PA6 stromal cells for 16 days; C-, No template control. Sox2, SRY-box 2; En1, Engrailed 1; Gapdh, glyceral-
dehydes-3-phosphate dehydrogenase; Aldh1a1, aldehyde dehydrogenase 1 family, member A1; Sdha, succinate dehydrogenase 
2, flavoprotein sububit; Tubb, β-tubulin; Actb, β-actin; Th, tyrosine hydroxylase; Msx1, homolog of Drosophila muscle segment 
homolog 1; Pitx2, paired-like homeodomain transcription factor 2.
BMC Genomics 2007, 8:46 http://www.biomedcentral.com/1471-2164/8/46numerous established or candidate markers of stem cells
the expression levels were not considerably higher (Log2
ratio < 1) in the hESC sample compared to the universal
reference RNA. For example, the expression of Nanog,
DNA (cytosine-5-)-methyltransferase 3α (Dnmt3a), MutS
homolog 2, colon cancer, nonpolyposis type 1 (E. coli)
(Msh2), Thy-1 cell surface antigen (Thy1), high-mobility
group box 2 (Hmgb2), transcription factor 3 (Tcf3),
Nanos homolog 1 (Nanos1), MyoD family inhibitor
(Mdfi), Calumenin (Calu) and soluble thymidine kinase
1 (Tk1) was detected in hES SA02 cells with Log2 ratio
value < 1. Expression levels of those genes range from
being inconsiderably higher to nearly equal to that in uni-
versal reference RNA sample. We believe that those find-
ings could be explained by cellular composition of
human universal reference RNA sample [42], which
includes pooled RNA samples from proliferating cells
(e.g., skin and testis cell lines). Thus, the relative differ-
ence between gene expression of certain markers of stem
cells in undifferentiated hESCs and universal reference
RNA is naturally decreased. Taken together, the gene
expression signature of hES SA02 cell line profiled by
NeuroStem Chip is indeed characteristic for pluripotent
stem cells, providing proof-of-concept.
Notably, comparison of expression profiles of undifferen-
tiated hESCs and hESC-derived cells committed toward
dopaminergic differentiation pathway by co-culturing
with SDIA for 16 days have revealed that many of the stem
cell marker genes mentioned above were down-regulated
in differentiation (Table 5). Expectedly, Hesx1, Grem1,
Dnmt3b, Utf1 and Nanog could be listed among these. At
the same time, numerous other genes, including Pitx2,
Dlk1 and Msx1 were up-regulated in the latter sample
([see Additional file 2], Figure 3). Table 1 lists 24
dopaminergic system-related entries (e.g., Ptx3, Th, Lhx1)
with gene expression up-regulated by Day 16 of hESC dif-
ferentiation protocol; few more genes have demonstrated
less prominent up-regulation (Log2 ratio values in the
range of 0.7/0.97–1.0). The gene expression profiles gen-
erated are therefore consistent with the results of earlier
studies utilizing hSC-derived samples with similar charac-
teristics [43,44]. Diversity of NeuroStem Chip entries
responsive to hESC commitment toward neuronal/
dopaminergic differentiation pathway clearly illustrates
the complexity of that pathway. The cell population
obtained after 16 day exposure to SDIA is highly heteroge-
neous. Only around 0.2% of the cells are TH-positive cells
(Figure 2). This heterogeneity, with an apparent presence
of residual pluripotent cells explains the presence of stem
cell marker genes, including homeobox transcription fac-
tor Nanog, as revealed by RT-PCR data (Figure 3). It would
be therefore impossible to apply the platform to identify
novel genes associated with the process of differentiation;
for that application, the genome-scale microarray plat-
forms (e.g., Affymetrix) are clearly superior. Nevertheless,
being based upon a moderate assay of pre-selected specific
gene targets, the comparative analysis of microarray data
derived from undifferentiated and dopaminergic differen-
tiate pathway-committed hESCs provides a valuable
cross-cut of complex relationship between factors driving
or indicative to neuronal/dopaminergic differentiation
[see Additional file 2].
RT-PCR analyses have validated the overall reliability of
NeuroStem microarray platform: all of the entries
detected in the hybridization experiments have demon-
strated similar trends when analyzed by RT-PCR means
(Figure 3). Those entries include Sox2, En1 and Nanog
(ratio of differentiated/undifferentiated hESC sample nor-
malized spot intensity < 0.75, down-regulated), Gadph,
Aldh1a1, Sdha, Tubb and Nestin (ratio .1.0, unchanged),
Actb, Th, Msx1 and Pitx2 (ratio >1.25, up-regulated).
Some of the housekeeping genes (Gapdh, Sdha, Tubb,
Actb) have somewhat different expression in undifferenti-
ated vs. differentiated cells, consistent with previous
reports on certain established housekeeping genes
(including Gapdh) being variable in human samples [45].
Importantly, all the observed gene expression trends were
similar in both microarray and RT-PCR. Our experiment
therefore confirms that the NeuroStem Chip microarray
platform can still identify gene expression changes related
to early stages of differentiation of hESC into dopaminer-
gic neurons.
Conclusion
Recent technological advances have led to DNA microar-
rays which contain over hundred thousand of spots of
DNA material, reaching a truly genomic scale. Highly spe-
cialized DNA microarrays of smaller scale (e.g. the Neu-
roStem Chip) still have an important role in the directed
studies in particular fields. Since they are significantly less
expensive, compared to many recognized large-scale plat-
forms (e.g. Affymetrix Human Genome platforms), they
have a clear advantage in routine work involving samples
from, e.g., multiple cell culture conditions. While there is
a risk that one will miss out on changes in genes previ-
ously not believed to be relevant to neural differentiation,
the restricted number of genes in the NeuroStem Chip
also simplifies analysis and adds power. NeuroStem Chip
is comparable to other stem cell-related focused microar-
ray platforms in regards to manufacturing costs and tech-
nical simplicity of the recommended hybridization
protocols. At the same time, it currently implies an advan-
tage in both the scale and the spectrum of pre-selected,
specific gene targets assayed. Some suggested areas of
application for NeuroStem microarray platform could be
the following: (i) characterization of the expression of
established, pre-selected gene targets in human stem cell
(hSC) lines, including newly derived ones, (ii) longitudi-Page 8 of 15
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BMC Genomics 2007, 8:46 http://www.biomedcentral.com/1471-2164/8/46Table 4: Top 25 genes up-regulated in hESC population, as compared to human universal reference RNA.
N Gene indexa Gene name Log2 Ratio S.E.M (%) Spot Error
1. Hesx1 Homeo box expressed in ES cells 1 4.11 5.76 0.0575
2. Grem1 Gremlin 1 homolog, cysteine knot superfamily 3.86 7.14 0.1012
3. Cdh6 Cadherin 6 (K-cadherin) 3.49 3.88 0.0186
4. Gja1 Gap junction protein, α1 (connexin 43) 3.49 7.10 0.0485
5. Htr2b 5-hydroxytryptamine (serotonin) receptor 2B 3.45 8.91 0.0655
6. Emx2 Empty spiracles homolog 2 (Drosophila) 3.24 6.10 0.1202
7. Epo Erythropoietin 3.22 9.67 0.0407
8. Fzd7 Frizzled homolog 7 (Drosophila) 3.08 4.99 0.0317
9. Kal1 Kallmann syndrome 1 sequence 3.05 3.10 0.0684
10. Auts2 Autism susceptibility candidate 2 3.03 7.49 0.0088
11. Zic3 Zic family member 3 heterotaxy 1 2.98 5.59 0.0709
12. Rds Retinal degeneration, slow 2.95 10.00 0.0756
13. Ddit4l DNA-damage-inducible transcript 4-like 2.90 4.90 0.0357
14. Crispld1 Cysteine-rich secretory protein LCCL domain containing 1 (LOC83690) 2.87 5.04 0.0990
15. Lrrn1 Leucine rich repeat neuronal 1 2.74 3.94 0.1002
16. Gpr23 G protein-coupled receptor 23 2.74 6.02 0.0702
17. Mgc16186 Hypothetical protein MGC16186 2.70 3.50 0.1592
18. Par1 Prader-Willi/Angelman region-1 2.69 18.44 0.0953
19. Nap1l3 Nucleosome assembly protein 1-like 3 2.69 4.00 0.0398
20. Cecr2 Cat eye syndrome critical region protein 2 2.65 6.40 0.0082
21. Fgfr2 Fibroblast growth factor receptor 2 2.64 5.11 0.0545
22. Klkb1 Kallikrein B, plasma (Fletcher factor) 1 2.63 9.96 0.0255
23. Calb1 Calbindin 1, 28kDa 2.61 1.45 0.0719
24. Fbn3 Fibrillin 3 2.60 12.68 0.0462
25. Id4 Inhibitor of DNA binding 4 2.50 6.44 0.0467
Only entries with spot intensity in hESC sample >100 are shown. Entries are sorted based on average Log2 ratio (after filtering for expression in all 
4 technical replicates). S.E.M., standard error of the mean expressed as percentage of the mean; Spot Error, estimate of the average measurement 
error for all spots for the given reporter across the 4 technical replicates.
a Italics indicates genes down-regulated (Log2 ratio < -1.0) in dopaminergic differentiation experiment.
nal quality control for maintained hSC populations, (iii)
following gene expression changes during differentiation
under defined cell culture conditions, and (iv) confirming
the success of differentiation into specific neuronal sub-
types. In addition, the NeuroStem Chip can be used to
characterize gene changes in intracerebral grafts of human
cells, even when they are transplanted into experimental
animals.
We specifically wish to stress that we are about to make
the NeuroStem Chip available at a non-profit cost to the
research community. We believe it has the potential to
become an important screening tool in the expanding
field of hSC studies in application to neurological/neuro-
degenerative disorders.
Methods
Human embryonic stem cell (hESC) cultures
Undifferentiated hESCs of SA02 (Sahlgrenska 2) line (Cel-
lartis AB, Göteborg, Sweden; see NIH Human Embryonic
Stem Cell Registry at [46]) were maintained over a mon-
olayer of human "feeder cells" (hFCs; human foreskin
fibroblasts, ATCC; cell line CCD-1112Sk). Feeder cells
were grown in hFC medium (Iscove's modified Dul-
becco's medium (IMDM) supplemented with 10% heat-
inactivated FCS (Stem Cell Technologies, USA) and 0.5%
Penicillin/Streptomycin mix) for 11 passages. One day
prior to hESC plating, hFC medium was washed away
from the hFCs, the latter were resuspended in a hESC pro-
liferation medium (VitroHES media (Vitrolife AB, Swe-
den) supplemented with 4 ng/ml human recombinant
basic FGF (hrbFGF, Biosource International, USA) and
plated in a central ring of gelatinized in vitro fertilization
(IVF) dishes with a cell density of 120,000 cells/dish. The
outer rings of the IVF dishes were filled with Dulbecco's
modified Eagle medium (DMEM) supplemented with
0.5% Penicillin/Streptomycin mix. One half of the culture
medium was replaced every other day. The cells were
maintained at 37°C, 5% CO2, 95% humidity settings.
Every 6 days, fragments of the hESC colonies (around 10–
14 colonies per dish, measuring around 0.015 × 0.015
mm) that had an unaltered morphology (indicating lack
of spontaneous differentiation) were mechanically cut
from dishes using stem cell knives/transfer pipettes
(SweMed Lab International AB, Sweden) and then plated
on fresh hFCs.Page 9 of 15
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BMC Genomics 2007, 8:46 http://www.biomedcentral.com/1471-2164/8/46Commitment of hESCs towards neuronal/dopaminergic 
differentiation pathway
Co-culturing with the PA6 stromal cell line (MC3T3-G2/
Pa6, from RIKEN Cell Bank Japan (RCB 1127), derived
from newborn mouse calvaria rapidly generates high
numbers of DA neurons from mouse and monkey ESCs
by an unknown mechanism named stromal-derived
inducing activity (SDIA; [28,29]). For differentiation
experiments, PA6 cells were plated on gelatine-coated T25
flasks at 16 × 103 cells/cm2 (400,000 cells/flask) density 2
days prior to introducing hESCs into the co-culture and
cultured at PA6 culturing media (containing minimum
essential medium alpha (α-MEM) supplemented with
10% FCS and 0.5% Penicillin/Streptomycin). Alterna-
tively, PA6 cells were plated over Type I collagen-coated
glass cover-slips placed in wells of 4-well-plates (50,000
cells/well, for immunocytochemical (ICC) analysis).
Three hours prior to initiation of co-culture, PA6 cells
were rinsed 3 times with PBS and media was replaced with
co-culture media (Glasgow's modified Eagle's media (G-
MEM) supplemented with 8% knock-out serum replace-
ment (KSR), 2 mM glutamine, 0.1 mM non-essential
amino-acids (NEAA), 1 mM pyruvate, 0.1 mM β-mercap-
toethanol (βME) and 4 ng/µl bFGF). Fragments of hESC
colonies (80–90 per flask; 4–5 per well of 4-well-plate)
presenting undifferentiated morphology were manually
passaged onto the confluent PA6 monolayer and cell co-
cultures were maintained at 37°C, 5% CO2, 95% humid-
NeuroStem Chip layout (a fragment)Fig re 4
NeuroStem Chip layout (a fragment). (A) Representative block (31 × 31 spots), as hybridized with actual hESC (Cy3)/universal 
reference (Cy5) sample. Arrow indicates β-actin (Actb) spot, which serves as a control for grid orientation; white boxes (B) 
highlight repetitive patterns, illustrating quadriplication of individual spots. (B, C) Dye-swap (hESC (Cy5)/universal reference 
(Cy3)) indicates accuracy of fluorescent dye incorporation and hybridization chemistry. Ier5, Immediate early response 5; 
Rab35, RAS-associated protein RAB35; Zbtb7, Zink finger and BTB domain containing 7. Spot-to-spot center distance 140 µm; 
average spot size 90–110 µm.Page 10 of 15
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Normalization and reproducibility of the NeuroStem Chip arraysFigure 5
Normalization and reproducibility of the NeuroStem Chip arrays. (A-B) Representative plots depict Log2(ratio) versus 
log10(intensities) prior to (A) and following (B) the normalization of one technical replicate (hESCs (Cy3) : universal reference 
(Cy5), 10:5 pmol). Green lines represent fitted values after normalization. (C) Centroid graph of a K-means classifier of 101 
genes clustered as highly up-regulated in the 4 technical replicates, indicating high reproducibility. Pink line is an average of the 
Log2 ratio values of the 101 genes. See [Additional file 1] for a list of genes in this cluster.
BMC Genomics 2007, 8:46 http://www.biomedcentral.com/1471-2164/8/46ity settings. One half of the co-culture medium was
replaced every other day for first 10 days, and daily
onwards.
Characterization of hESCs and hESC-derived cells by 
immunocytochemistry (ICC) and RT-PCR
IVF dishes with hESCs grown atop hFCs and 4-well plate
dishes with hESCs growing atop PA6 cells were fixed with
4% paraformaldehyde (PFA) for 15 minutes at the day of
passage/harvest (Day 6 of hESC/hFC co-culturing) and
Day 16 of co-culturing with PA6 cells, respectively. Cells
were pre-incubated with blocking solution containing
PBS, 0.5% Triton X-100 and 5% of donkey serum. They
were then incubated with primary antibodies in blocking
solution overnight at room temperature. After three
washes with PBS, cells were incubated with the donkey
anti-rabbit IgG conjugated with FITC or anti-mouse Cy3
(1:200, Jackson ImmunoResearch Laboratories). Cells
were then washed once with PBS, incubated with 1:1000
DAPI in PBS for 10 minutes, followed by another wash
with PBS. Coverslips were mounted onto glass slides with
PVA mounting medium containing anti-fading reagent
DABCO. The following primary antibodies were used:
mouse anti-Oct3/4 (1:500, Santa Cruz Biotechnology
Inc.); rabbit anti-Ki67 (1:200, Novocastra Ltd.); rabbit
anti-TH (1:500, Chemicon). Immunostained cell cultures
were visualized using a Zeiss fluorescent microscope
attached to a Nikon digital camera.
Using RT-PCR, all RNA samples used in this study were
tested negative for the presence of gDNA (data not
shown). The intron-spanning primers for RT-PCR were
selected from published works or designed using Oligo
4.0 software (Molecular Biology Insight) or Clone Man-
ager Suite 7.1 (Sci Ed Software, NC, USA) and ordered
from TAG Copenhagen A/S, Denmark, as the following:
Sox2, SRY-box 2: 5'-TAC CTC TTC CTC CC CTC CA-3', 5'-
ACT CTC CTC TTT TGC ACC CC-3'; En1, Engrailed 1: 5'-
AAG GGA CGA AAC TGC GAA CTC C-3', 5'-GAC ACG
AAA GGA AAC ACA CAC TCT CG-3' [47]; Nanog: 5'-TGC
TTA TTC AGG ACA GCC T-3', 5'-TCT GGT CTT CTG TTT
CTT GAC T-3' [48]; Gapdh, glyceraldehydes-3-phosphate
dehydrogenase: 5'-GGA AGG TGA AGG TCG GAG TCA A-
3', 5'-GAT CTC GCT CCT GGA AGA TGG T-3'; Aldh1A1,
aldehyde dehydrogenase 1 family, member A1: 5'-GGG
CAG CCA TTT CTT CTC AC-3', 5'-CTT CTT AGC CCG CTC
AAC AC-3' [49]; Sdha, succinate dehydrogenase: 5'-TGG
GAA CAA GAG GGC ATC TG-3', 5'-CCA CCA CTG CAT
CAA ATT CAT G-3' [50]; Tubb, β-tubulin: 5'-CTC ACA
AGT ACG TGC CTC GAG-3', 5'-GCA CGA CGC TGA AGG
TGT TCA-3'; Nestin: 5'-AGA GGG GAA TTC CTG CT GAG-
3', 5'-CTG AGG ACC AGG ACT CTC TA-3' [47]; Actb, β-
actin: 5'-CAT CGA GCA CGG CAT CGT CA-3', 5'-TAG
CAC AGC CTG GAT AGC AAC-3' [51]; Th, Tyrosine
hydroxylase: 5'-CGA GCT GTG AAG GTG TTT G-3', 5'-TTG
GTG ACC AGG TGA TGA C-3'; Msx1, homolog of Dro-
sophila muscle segment homolog 1: 5'-CTC AAG CTG CCA
GAA GAT GC-3', 5'-TCC AGC TCT GCC TCT TGT AG-3';
Pitx2, paired-like homeodomain transcription factor 2: 5'-
ACC TTA CGG AAG CCC GAG TC-3', 5'-TGG ATA GGG
AGG CGG ATG TA-3' [49]. cDNA was synthesized from 1
mg of total RNA using SuperScript II (Invitrogen), and RT-
PCR amplifications were performed using the MiniOpti-
con system (Bio-Rad) with REDTaq Polymerase (Sigma-
Aldrich) essentially as described by the manufacturer. Fol-
lowing initial denaturation for 5 min at 95°C, DNA
Table 5: Embryonic stem cell marker genes expressed in hES SA02 cell line, as detected by the NeuroStem Chip analysis
N Gene indexa Gene name Log2 Ratio S.E.M (%)
1. Hesx1 Homeo box expressed in ES cells 1 4.11 5.76
2. Grem1 Gremlin 1 homolog, cysteine knot superfamily 3.86 7.14
3. Gja1 Gap junction protein, α1 (connexin 43) 3.49 7.10
4. Zic3 Zic family member 3 heterotaxy 1 2.98 5.59
5. Dnmt3b DNA (cytosine-5)-methyltransferase 3β 2.26 6.25
6. Sfrp1 Secreted frizzled-related protein 1 2.01 8.80
7. Kiaa1573 KIAA1573 protein 1.98 2.48
8. Dppa4 Developmental pluripotency associated 4 1.97 2.80
9. Sox2 SRY (sex determining region Y)-box 2 1.86 12.44
10. Foxo1a Forkhead box O1A (rhabdomyosarcoma) 1.85 9.15
11. Hmgb1 High-mobility group box 1 1.84 1.71
12. Ctbp2 C-terminal binding protein 2 1.77 9.16
13. Lin28 Lin-28 homolog (C. elegans) 1.52 20.32
14. Utf1 Undifferentiated embryonic cell transcription factor 1.21 9.28
15. Lefty1 Left-right determination factor 1 1.06 8.72
Only entries with spot intensity in hESC sample >100 and Log2 ratio >1 are shown. Entries are sorted based on average Log2 ratio (after filtering 
for expression in all 4 technical replicates). S.E.M., standard error of the mean expressed as percentage of the mean.
a Italics indicates genes down-regulated (< -1.0 Log2 ratio) in dopaminergic differentiation experiment. Nanog is down-regulated with Log2 ratio < -
0.6.Page 12 of 15
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Aldh1a1), 33 (Sox2, Nestin, Th, Msx1), 32 (Tubb, Pitx2),
27 (Sdha), 25 (Actb) or 22 (Gapdh) cycles of 1 min at
95°C, 1 min at 55°C (En1, Pitx2), 57°C (Sox2, Nanog,
Sdha, Nestin), 58°C (Tubb), 58.5°C (Aldh1a1, Th) or
59°C (Gapdh, Actb, Msx1), and 1 min at 72°C. The final
extension was 5 min at 72°C. Twenty µl volumes of RT-
PCR products were analyzed by electrophoresis at 1% aga-
rose gels and visualized by ethidium bromide staining.
RNA purification and fluorescent dye incorporationFor
RNA purification of undifferentiated hESCs, the latter
were mechanically separated from hFCs, collected in a
500 µl volume of VitroHES media, rinsed in PBS buffer
and spun down at 300 rcf for 5 min. hESC-derived cells
grown atop PA6 cells were harvested using a papain disso-
ciation kit (Worthington Biochemical Corporation),
rinsed in PBS buffer and spun down as described above.
The resulting cell pellets were resuspended in RLT buffer
(Qiagen, USA), passed through the shredder column
(Qiagen) and stored at -80°C until the RNA sample was
purified following the RNeasy Micro Kit (Qiagen) proto-
col (without carrier RNA); with DNase I (Quiagen) treat-
ment incorporated to the latter. RNA integrity was tested
using both ND-1000 specrophotometer (NanoDrop,
USA) and RNA Nano LabChip/2100 Bioanalyzer system
(Agilent Technologies, USA).
Fluorescent label (24 nmol of the Cyanine 3-CTP (Cy3);
PerkinElmer, USA) was incorporated to 350–500 ng of
total RNA amplified using Low RNA Input Fluorescent
Linear Amplification Kit (Agilent Technologies), generally
following the kit manufacturer's protocol. Similarly, 24
nmols of the Cyanine 5-CTP (Cy5; PerkinElmer) fluores-
cent label were incorporated to 400 ng sample of Human
Universal Reference RNA (Stratagene, USA); in addition,
dye-swap replicate amplification were performed. Ampli-
fied fluorescent cRNA samples were purified using RNeasy
mini-columns (Quiagen), and fluorescence of the eluted
products was measured using ND-1000 specrophotome-
ter (NanoDrop).
Microarray technology
Long oligonucleotide probes (69–71 nucleotides) match-
ing gene targets of interest were selected from Operon V2
and V3 human AROS sets (Operon Biotechnologies Inc.,
USA). Arrays were produced by the SweGene DNA Micro-
array Resource Centre, Department of Oncology at Lund
University (Sweden) using a MicroGrid II 600R arrayer fit-
ted with MicroSpot 10 K pins (Harvard BioRobotics,
USA). Printing was performed in a temperature- (18–
20°C) and humidity- (44–49% RH) controlled area on
Corning UltraGAPS aminosilane slides (Corning Inc.,
USA) with 140 µm spot-to-spot centerdistance and 90–
110 µm average spot size. Following printing, arrays were
dried for 48 hours andstored in a dessicator until used.
Microarray slides were UV-cross-linked (800 mJ/cm2),
pre-hybridizedwith fluorescently labeled samples using
the Pronto! Universal Microarray Hybridization Kit
(Corning) and subsequently hybridized with test (Cy3-
labeled)/reference (Cy5-labeled) RNA samples (or in
reverse dye-labeling order) at 42°C for 17 h using a MAUI
hybridization station (BioMicro Systems Inc., USA) and
the Pronto! Universal Microarray Hybridization Kit, gen-
erally following manufacturer's instructions, with several
minor adaptations [31].
Data acquisition and statistical analysis
Immediately following the washing steps, the fluores-
cence intensities were measured using a confocal laser
scanner (G2505B, Agilent Technologies). After image for-
matting by Tiff Image Channel Splitter Utility (Agilent
Technologies) and grid annotation, a complete set of
spots was visually inspected for each slide. Using GenePix
Pro (Molecular Devices Corp. USA) flags for artifactual
spots were annotated for each spot. Median pixel intensity
minus the median local background for both dyes was
used to obtain a test over reference intensity ratio. Data
normalization was performed per array subgrid using
LOWESS curve fitting with a smoothing factor of 0.33
[52,53]. All normalizations, filtering, merging of technical
replicates and analyses were performed in the BioArray
Software Environment database [32]. To visualize sample-
dependent variation of spot intensities, data was
uploaded to the TIGR MultiExperiment Viewer (MEV;
[34]).
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